ATAIHealthcare · BiotechnologyThe 13 Wall Street analysts covering Atai Beckley, Inc. hold a median 12-month price target of $7.75 — +5.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Atai Beckley, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ATAI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +5.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Deutsche Bank | Downgrade | Hold | $12 → $8.00 |
| 20 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | $25 → $7.50 |
| 20 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 July 2026 | Guggenheim | Downgrade | Neutral | — |
| 17 July 2026 | Guggenheim | Downgrade | Neutral | — |
| 17 July 2026 | Jefferies | Downgrade | Hold | — |
| 17 July 2026 | Jefferies | Downgrade | Hold | $10 → $7.50 |
| 17 July 2026 | Jones Trading | Downgrade | Hold | — |
| 17 July 2026 | Jones Trading | Downgrade | Hold | — |
| 16 July 2026 | Canaccord Genuity | Downgrade | Hold | $8.00 |
| 16 July 2026 | Canaccord Genuity | Downgrade | Hold | — |
| 16 July 2026 | Maxim Group | Downgrade | Hold | — |
| 16 July 2026 | Maxim Group | Downgrade | Hold | — |
| 16 July 2026 | Needham | Downgrade | Hold | — |
| 16 July 2026 | Needham | Downgrade | Hold | — |
| 7 July 2026 | Canaccord Genuity | Maintains | Buy | $15 → $17 |
| 7 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 July 2026 | Jefferies | Maintains | Buy | $10 |
| 6 July 2026 | Jefferies | Maintains | Buy | — |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATAI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 2% of US stocks
Cheaper than 6% of US stocks
Cheaper than 89% of US stocks
Higher than 95% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atai Beckley, Inc. has a market value of $307.8M and an enterprise value of $2.5B.
Revenue in the twelve months to 30 June 2026: $4.5M. The latest quarter grew 137.0% year on year.
Net income over the same four quarters: −$668.3M, a −14940.4% net margin.
Diluted earnings per share, trailing twelve months: $−2.18.
Free cash flow in the twelve months to 30 June 2026: −$132.6M.
Trailing P/E: −0.3×; forward P/E: −15.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Atai Beckley, Inc. employs 99 people — $45K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Atai Beckley, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Atai Beckley, Inc. (ATAI) reported earnings 30 days ago, and its stock has risen 0.8% since that report. The item notes the recent performance and looks ahead to what may come next for the company.
Why it matters — ATAI watchers would care because the item documents the stock's modest post-earnings movement and signals an upcoming assessment of the company's next steps.
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to develop a new long-term growth driver beyond its cardiometabolic therapies.
Why it matters — An ATAI watcher would care because a major pharmaceutical competitor is increasing focus on neuroscience, a space where ATAI operates.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is not sure that there is a lot of upside in Atai Beckley Inc. (NASDAQ:ATAI). The comment was made during a segment on the financial network.
Why it matters — A noted television commentator's cautious view on the stock could draw attention among those following ATAI, though he expressed uncertainty rather than a definitive outlook.
Kahn Swick & Foti, LLC is investigating the adequacy of the price and process in the proposed sale of AtaiBeckley Inc. to Eli Lilly and Company, under which ATAI shareholders would receive $6.75 per share in cash plus up to $2.50 per share via a Contingent Value Right.
Why it matters — ATAI watchers would care because the investigation could affect the terms or outcome of the proposed acquisition of the company.
Wall Street analysts' mean price target for Atai Beckley Inc (ATAI) points to a 31.5% upside in the stock, according to Zacks Investment Research. While the report notes this price-target metric has not proven highly effective historically, strong agreement among analysts in raising earnings estimates suggests a potential upside.
Why it matters — ATAI watchers would care because the report highlights what analyst expectations indicate for the stock and signals that analysts are revising earnings estimates upward.
The 13 Wall Street analysts covering Atai Beckley, Inc. have a median 12-month price target of $7.75, with estimates ranging from $7.45 to $9.25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Atai Beckley, Inc., 1 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atai Beckley, Inc. 26 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Atai Beckley, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +5.4% from the last close, and Ticker Nerd's factor model ranks Atai Beckley, Inc. 26 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Atai Beckley, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.45 to $9.25 over the next 12 months.
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing mental health treatments.
The most recent item we track (Zacks Investment Research, 10 Sept 2026): "Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?". Atai Beckley, Inc. (ATAI) reported earnings 30 days ago, and its stock has risen 0.8% since that report. The item notes the recent performance and looks ahead to what may come next for the company.
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing mental health treatments. The company concentrates on rapid-acting, durable, and convenient therapies designed to address difficult-to-treat psychiatric conditions, including depression, treatment-resistant depression, social anxiety disorder, and other central nervous system disorders. Its current pipeline includes investigational programs based on psychedelic-inspired and neuroplasticity-driven compounds, developed through internal research and strategic collaborations. AtaiBeckley Inc. also works across discovery, clinical development, and potential commercialization activities, reflecting its role in advancing new therapeutic options within the mental health and neuroscience markets. Headquartered in New York, AtaiBeckley Inc. operates as part of the broader biotechnology and pharmaceutical sector, where it is known for targeting unmet needs in mental health care with a specialized, research-focused portfolio.
CEO Dr. Srinivas G. Rao M.D., Ph.D. · 99 employees · United States · https://www.ataibeckley.com